These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 26413878)
1. A cholesterol-lowering VLP vaccine that targets PCSK9. Crossey E; Amar MJA; Sampson M; Peabody J; Schiller JT; Chackerian B; Remaley AT Vaccine; 2015 Oct; 33(43):5747-5755. PubMed ID: 26413878 [TBL] [Abstract][Full Text] [Related]
2. A Therapeutic Peptide Vaccine Against PCSK9. Pan Y; Zhou Y; Wu H; Chen X; Hu X; Zhang H; Zhou Z; Qiu Z; Liao Y Sci Rep; 2017 Oct; 7(1):12534. PubMed ID: 28970592 [TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
15. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Shen L; Peng H; Xu D; Zhao S Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522 [TBL] [Abstract][Full Text] [Related]
16. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study. Simonen P; Stenman UH; Gylling H Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271 [TBL] [Abstract][Full Text] [Related]
17. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586 [TBL] [Abstract][Full Text] [Related]
18. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
19. Understanding PCSK9 and anti-PCSK9 therapies. McKenney JM J Clin Lipidol; 2015; 9(2):170-86. PubMed ID: 25911073 [TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition in patients with hypercholesterolemia. Desai NR; Sabatine MS Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]